Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare OPPS Pass-Through Payment 50% Cut Likely On Jan. 1

This article was originally published in The Gray Sheet

Executive Summary

The Health Care Financing Administration is expected to issue a rule in early November effecting a 50% cut in special "pass-through" payments under the hospital outpatient prospective payment system (OPPS) for breakthrough medical devices, drugs and radiopharmaceuticals. The cuts would take effect Jan. 1, 2001.

You may also be interested in...



Medicare Proposal Lacks Cost Data, Imposes Limitations On Industry Rebuttal

CMS' omission of cost-and-utilization data related to its hospital outpatient prospective system (OPPS) proposal makes it difficult for device manufacturers to bolster their arguments against a pro-rata reduction.

Medicare Proposal Lacks Cost Data, Imposes Limitations On Industry Rebuttal

CMS' omission of cost-and-utilization data related to its hospital outpatient prospective system (OPPS) proposal makes it difficult for device manufacturers to bolster their arguments against a pro-rata reduction.

HCFA Decision On OPPS Pro-Rata Reduction Expected By November

The Health Care Financing Administration will need to decide by November whether it is necessary to implement a pro-rata reduction in pass-through payments for the hospital outpatient prospective payment system (OPPS) in 2002.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT014013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel